|
|
|
The 3rd World Congress on
Controversies in Ophthalmology (COPHy)
Anterior Segment, Retina, Glaucoma
Istanbul, Turkey, March 22 - 25, 2012 |
|
 |
| Symposia |
 |
|
|
Breakfast Symposium (not for CME) A New Way to Look at Symptomatic VMA and its Treatment
(Sponsored by Thrombogenics)
Room: Fuji 1
07:15-08:15
Moderator: A. Loewenstein, Israel
|
|
07:15-07:25 |
Case studies
A. Loewenstein, Israel
|
| 07:25-07:35 |
The role of the vitreous in retinal diseases
M. DeSmet, Switzerland
|
|
07:35-07:45 |
Overview of enzymatic vitreolysis
W. Mieler, USA
|
| 07:45-07:55 |
New option for the treatment of vitreomacular traction
F. Bandello, Italy
|
| 07:55-08:05 |
New option for the treatment of full-thickness macular holes
A. Tufail, UK
|
|
08:05-08:15 |
Case studies and discussion
Panel
|
|
Controversies in Ophthalmology - Management of RVO
(Sponsored by Allergan)
Room: Fuji 1 & 2
12:15-13:45
Chairpersons: G. Coscas, France; A. Loewenstein, Israel
|
|
12:15-12:20
|
Welcome, Introductions & Objectives
Chairpersons
|
| 12:20-12:40
|
RVO Disease Management Debate
Is it all about VEGF?
S. Bressler, USA
Is it all about inflammatory mediators?
J. Ambati, USA
Rebuttal
|
|
|
What to address first? The underlying inflammation or the fluid?
G. Coscas, France
|
| 12:50-13:00
|
How to choose a first-line treatment? Pros and Cons
A. Loewenstein, Israel
|
| 13:00-13:30 |
Open Discussion & Debate
All Speakers
|
|
1330-13:35
|
Close and Summary
Chairpersons
|
|
Dietary Supplements for Common Eye Diseases
(Sponsored by Bausch & Lomb)
Room: Fuji 2
10:30-11:30
|
|
10:30-10:45
|
Dietary supplements in AMD: AREDS Formulation; Lutein, zeaxanthin, and omega-3 fatty acids
S. Bressler, USA |
| 10:45-10:50 |
Q&A from the audience, panel, chairpersons
|
|
10:50-11:05
11:05-11:10
|
Dietary supplements in diabetic retinopathy
N. Bressler, USA
Q&A from the audience, panel, chairpersons
|
|
11:10-11:25
11:25-11:30 |
Potential impact of dietary supplements and mortality
J. Alio, Spain
Q&A from the audience, panel, chairpersons
|
|
|
Q&A from the audience and closing remarks
|
|
Management of Dry Eye
(Sponsored by Allergan)
Room: Fuji 1
11:30-12:45
|
|
11:30-11:45
|
Definition and classification of dry eye syndrome
E. Messmer, Germany
|
|
|
Pathology of dry eye syndrome: Osmolarity & Liquid Deficiency
P. Aragona, Italy
|
| 12:00-12:15
|
Pathology of dry eye syndrome: Inflammation
Y. Akova, Turkey
|
| 12:15-12:30 |
Current trends in the treatment of dry eye syndrome
K. Boboridis, Greece
|
|
12:30-12:45 |
Case studies & Discussion
Moderator: E. Messmer, Germany
Case 1
P. Aragona, Italy
Case 2
Y. Akova, Turkey
Case 3
K. Boboridis, Greece
|
|
Individualized therapy - the modern standard in AMD care
(Sponsored by Novartis)
Room: Fuji 2
13:45-14:45
Chairperson: F. Bandello, Italy
|
|
13:45-13:50
|
Introduction
F. Bandello, Italy
|
|
13:50-14:00
|
Fixed to flexible: The evolution of VEGF regimens in wet AMD
F. Bandello, Italy
|
|
14:00-14:10
|
How can modern monitoring techniques support individualised treatment of wet AMD?
M. Larsen, Denmark
|
| 14:10-14:20 |
The Great Safety Debate: What is the role of emerging data on VEGF inhibition in wet AMD?
V. Chong, UK
|
|
14:20-14:30
14:30-14:45 |
Informing therapy choices in wet AMD through emerging comparative data
P. Lanzetta, Itlay
Panel Discussion
|
|
The Management of Neovascular AMD in 2011 and Beyond
(Sponsored by Bayer)
Room: Fuji 2
15:15-16:15
Chairperson: A. Loewenstein, Israel
|
|
15:15-15:20
15:20-15:30
15:30-15:45
|
Introduction to symposium
A. Loewenstein, Israel
VEGF Trap feature of molecule
B. Eldem, Turkey
The burden of the disease (wAMD)
P. Lanzetta, Italy
|
|
15:45-16:05
16:05-16:15 |
Updated clinical trial results from VIEW studies (based on Year 1 and year 2 results)
A. Loewenstein, Israel
Panel Q&A
A. Loewenstein, Israel
B. Eldem, Turkey
P. Lanzetta, Italy
|
|
|
|
|
WebStudio.co.il